Literature DB >> 12805462

Human immunodeficiency virus type 2 reverse transcriptase activity in model systems that mimic steps in reverse transcription.

Klara Post1, Jianhui Guo, Kathryn J Howard, Michael D Powell, Jennifer T Miller, Amnon Hizi, Stuart F J Le Grice, Judith G Levin.   

Abstract

Human immunodeficiency virus type 2 (HIV-2) infection is a serious problem in West Africa and Asia. However, there have been relatively few studies of HIV-2 reverse transcriptase (RT), a potential target for antiviral therapy. Detailed knowledge of HIV-2 RT activities is critical for development of specific high-throughput screening assays of potential inhibitors. Here, we have conducted a systematic evaluation of HIV-2 RT function, using assays that model specific steps in reverse transcription. Parallel studies were performed with HIV-1 RT. In general, under standard assay conditions, the polymerase and RNase H activities of the two enzymes were comparable. However, when the RT concentration was significantly reduced, HIV-2 RT was less active than the HIV-1 enzyme. HIV-2 RT was also impaired in its ability to catalyze secondary RNase H cleavage in assays that mimic tRNA primer removal during plus-strand transfer and degradation of genomic RNA fragments during minus-strand DNA synthesis. In addition, initiation of plus-strand DNA synthesis was much less efficient with HIV-2 RT than with HIV-1 RT. This may reflect architectural differences in the primer grip regions in the p66 (HIV-1) and p68 (HIV-2) palm subdomains of the two enzymes. The implications of our findings for antiviral therapy are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12805462      PMCID: PMC164806          DOI: 10.1128/jvi.77.13.7623-7634.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  Structure of a DNA analog of the primer for HIV-1 RT second strand synthesis.

Authors:  G W Han; M L Kopka; D Cascio; K Grzeskowiak; R E Dickerson
Journal:  J Mol Biol       Date:  1997-06-27       Impact factor: 5.469

2.  Possible roles of HIV-1 nucleocapsid protein in the specificity of proviral DNA synthesis and in its variability.

Authors:  M Lapadat-Tapolsky; C Gabus; M Rau; J L Darlix
Journal:  J Mol Biol       Date:  1997-05-02       Impact factor: 5.469

3.  Human immunodeficiency virus type 1 nucleocapsid protein promotes efficient strand transfer and specific viral DNA synthesis by inhibiting TAR-dependent self-priming from minus-strand strong-stop DNA.

Authors:  J Guo; L E Henderson; J Bess; B Kane; J G Levin
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Alanine-scanning mutations in the "primer grip" of p66 HIV-1 reverse transcriptase result in selective loss of RNA priming activity.

Authors:  M D Powell; M Ghosh; P S Jacques; K J Howard; S F Le Grice; J G Levin
Journal:  J Biol Chem       Date:  1997-05-16       Impact factor: 5.157

5.  Mutating a conserved motif of the HIV-1 reverse transcriptase palm subdomain alters primer utilization.

Authors:  M Ghosh; J Williams; M D Powell; J G Levin; S F Le Grice
Journal:  Biochemistry       Date:  1997-05-13       Impact factor: 3.162

6.  Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNase H function.

Authors:  C Palaniappan; M Wisniewski; P S Jacques; S F Le Grice; P J Fay; R A Bambara
Journal:  J Biol Chem       Date:  1997-04-25       Impact factor: 5.157

7.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

Authors:  H Huang; R Chopra; G L Verdine; S C Harrison
Journal:  Science       Date:  1998-11-27       Impact factor: 47.728

8.  Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution.

Authors:  J Ding; K Das; Y Hsiou; S G Sarafianos; A D Clark; A Jacobo-Molina; C Tantillo; S H Hughes; E Arnold
Journal:  J Mol Biol       Date:  1998-12-11       Impact factor: 5.469

Review 9.  Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2.

Authors:  J Milton; M J Slater; A J Bird; D Spinks; G Scott; C E Price; S Downing; D V Green; S Madar; R Bethell; D K Stammers
Journal:  Bioorg Med Chem Lett       Date:  1998-10-06       Impact factor: 2.823

10.  Generation of HIV-1/HIV-2 cross-reactive peptide antisera by small sequence changes in HIV-1 reverse transcriptase and integrase immunizing peptides.

Authors:  M Klutch; A M Woerner; C J Marcus-Sekura; J G Levin
Journal:  J Biomed Sci       Date:  1998       Impact factor: 8.410

View more
  7 in total

1.  High frequency of genetic recombination is a common feature of primate lentivirus replication.

Authors:  Jianbo Chen; Douglas Powell; Wei-Shau Hu
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Physiological Mg2+ Conditions Significantly Alter the Inhibition of HIV-1 and HIV-2 Reverse Transcriptases by Nucleoside and Non-Nucleoside Inhibitors in Vitro.

Authors:  Vasudevan Achuthan; Kamlendra Singh; Jeffrey J DeStefano
Journal:  Biochemistry       Date:  2016-12-27       Impact factor: 3.162

3.  Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.

Authors:  Daniel M Held; Jay D Kissel; Sarah J Thacker; Daniel Michalowski; Dayal Saran; Jianfei Ji; Richard W Hardy; John J Rossi; Donald H Burke
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

4.  SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates.

Authors:  Hichem Lahouassa; Waaqo Daddacha; Henning Hofmann; Diana Ayinde; Eric C Logue; Loïc Dragin; Nicolin Bloch; Claire Maudet; Matthieu Bertrand; Thomas Gramberg; Gianfranco Pancino; Stéphane Priet; Bruno Canard; Nadine Laguette; Monsef Benkirane; Catherine Transy; Nathaniel R Landau; Baek Kim; Florence Margottin-Goguet
Journal:  Nat Immunol       Date:  2012-02-12       Impact factor: 25.606

5.  Novel inhibitors of human immunodeficiency virus type 2 infectivity.

Authors:  Lauren B Beach; Jonathan M Rawson; Baek Kim; Steven E Patterson; Louis M Mansky
Journal:  J Gen Virol       Date:  2014-08-07       Impact factor: 3.891

6.  Fidelity of plus-strand priming requires the nucleic acid chaperone activity of HIV-1 nucleocapsid protein.

Authors:  Klara Post; Besik Kankia; Swathi Gopalakrishnan; Victoria Yang; Elizabeth Cramer; Pilar Saladores; Robert J Gorelick; Jianhui Guo; Karin Musier-Forsyth; Judith G Levin
Journal:  Nucleic Acids Res       Date:  2009-01-21       Impact factor: 16.971

7.  Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

Authors:  Paul L Boyer; Stefan G Sarafianos; Patrick K Clark; Eddy Arnold; Stephen H Hughes
Journal:  PLoS Pathog       Date:  2006-02-17       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.